Alto Neuroscience Inc. shares hit a record $35.42 on Wednesday, capping a year of extraordinary gains driven by clinical progress and a $100 million equity raise. The biotech, which trades under the ticker ANRO, has surged 793.91% over the past 12 months and 92.6% year-to-date, lifting its market capitalization to $1.38 billion.
The rally follows Alto’s announcement of a $100 million stock offering priced at $26.48 per share, a move aimed at funding further development of its pipeline. Analysts at H.C. Wainwright responded by raising the company’s price target to $55 while maintaining a Buy rating. The upgrade cited the company’s ALTO-207 development plan, which includes trials targeting treatment-resistant depression.
Supporting the upbeat outlook, an independent clinical trial published in Nature Medicine demonstrated that the dopamine agonist pramipexole significantly reduced anhedonia—a core symptom of mood disorders—in patients. The study, conducted by Lund University, adds to the growing body of evidence around Alto’s therapeutic approaches.
The company also appointed Andrew Miller, Ph.D., to its Board of Directors. Miller brings prior experience from Karuna Therapeutics, where he contributed to the development of COBENFY, a treatment for schizophrenia. Alto’s stock has entered overbought territory based on its Relative Strength Index (RSI), according to InvestingPro, which also flagged potential overvaluation relative to its fair value estimate.
Alto Neuroscience focuses on precision neuroscience, developing treatments tailored to individual patient biology. The recent milestones underscore investor confidence in its pipeline, though the sharp rally has raised questions about valuation sustainability amid broader biotech sector volatility.
